Project Grant HT94252310686
Award Date
9/30/23
Completion Date
9/29/27
Dollars Obligated
$2.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Valhalla, NY 10595, USA
Similar Awards
This federal Project Grant award, valued at $1,599,743.00 and funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research on the identification and circumvention of resistance after donor-derived ex vivo expanded natural killer (NK) cells and haploidentical hematopoietic cell transplantation (haplo-HCT) in children and young adults with high-risk acute myeloid leukemia (AML). The principal awardee is New York Medical College, a...
New York University School of Medicine was awarded a $762,750 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund a research project titled "BEYOND VEXAS AND UBA1: IDENTIFICATION OF NOVEL DRIVERS OF MDS AUTOIMMUNE SYNDROMES" from June 15, 2023 through June 14, 2026. The grant supports research to identify novel drivers of myelodysplastic syndromes, blood disorders that can progress...
The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, was awarded a $656,272 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research aimed at optimizing PD-1 immunotherapy through increased T cell regeneration and reduced antigen load. This 2-year project will be conducted in New York, NY from September 1, 2023 to August 31, 2025. The Military Medical...
This Federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $504,678 in funding to the Mountain Home Research & Education Corporation for a research project titled "LONG NONCODING RNAS IN VIRAL LYMPHOMAS". The award period runs from September 30, 2023 to September 29, 2025. The project aims to conduct basic, translational, and clinical research related to military medicine, with a focus on...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The federal Project Grant award, totaling $532,916, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives at the University of California, San Diego (UCSD) focused on "COMBINED EPIGENETIC REPROGRAMMING AND IMMUNOTHERAPY TO TACKLE HIGH-RISK MULTIPLE MYELOMA." The project aims to explore innovative approaches to disease prevention, diagnosis, treatment, and...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
Albany Medical College received a $733,500 Project Grant award from the Defense Health Agency dated June 1, 2023 through May 31, 2026 under the Military Medical Research and Development federal grant program (CFDA 12.420). Through this award, Albany Medical College will conduct research investigating medical solutions for the battlefield by harnessing RVE1 to treat bone marrow failure. The Military Medical Research and Development program aims to transform military and public health through...